Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Pimitespib |
Synonyms | |
Therapy Description |
Pimitespib (TAS-116) is a selective inhibitor of HSP90-alpha and HSP90-beta, which may lead to decreased tumor growth (PMID: 25416789, PMID: 31857719, PMID: 31536852, PMID: 30679388). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Pimitespib | TAS-116|TAS116 | HSP90 Inhibitor 35 | Pimitespib (TAS-116) is a selective inhibitor of HSP90-alpha and HSP90-beta, which may lead to decreased tumor growth (PMID: 25416789, PMID: 31857719, PMID: 31536852, PMID: 30679388). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05245968 | Phase I | Imatinib Sunitinib Pimitespib Imatinib + Pimitespib | A Study of Pimitespib in Combination With Imatinib in Patients With GIST (CHAPTER-GIST-101) | Recruiting | AUS | 4 |
NCT02965885 | Phase I | Pimitespib | A Study of TAS-116 in Patients With Solid Tumors | Completed | USA | ITA | GBR | 0 |